| 11/05 | uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |  |
| 11/05 | UniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 02/05 | uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell .. | |
| 02/05 | UniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell .. | |
| 02/05 | UNIQURE N: 2021 Dutch Statutory IFRS Financials | |
| 02/05 | Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $1.8M | |
| 02/05 | UniQure Reports Wider Q1 Loss, Higher Revenue | |
| 02/05 | UNIQURE N.V. Management's Discussion and Analysis of Financial Condition and Results
o.. | |
| 02/05 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 02/05 | UNIQURE: Q1 Earnings Snapshot | |
| 02/05 | uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Pr.. | |
| 02/05 | UniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Pr.. | |
| 29/03 | CSL Behring - European Medicines Agency Commences Review of Novel Gene Therapy Candidat.. | |
| 28/03 | European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene.. | |
| 22/03 | UNIQURE N: Announces Completion of Patient Enrollment in the First Two Cohorts of its Pha.. | |
| 22/03 | UNIQURE N.V.: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 21/03 | UniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phas.. | |
| 21/03 | UniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phas.. | |
| 17/03 | UniQure Shares Gain After Upgrade by UBS | |
| 03/03 | Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer | |
| 28/02 | UNIQURE N: Announces 2021 Financial Results and Highlights Recent Company Progress - Form.. | |
| 25/02 | SECTOR UPDATE: Health Care Stocks Mixed Pre-Bell Friday | |
| 25/02 | UniQure Swings to 2021 Profit, Revenue Increases; Shares Rise Pre-Bell | |
| 25/02 | UNIQURE N.V. Management's Discussion and Analysis of Financial Condition and Results
o.. | |
| 25/02 | UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2021 | |
| 25/02 | UniQure Announces 2021 Financial Results and Highlights Recent Company Progress | |
| 08/02 | UNIQURE N: Announces Dosing of First Patients in European Open-Label Clinical Trial of AM.. | |
| 08/02 | UNIQURE N.V.: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 07/02 | Uniqure Doses First Two Patients in Huntington's Disease Trial | |
| 07/02 | UniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT.. | |
| 07/02 | UniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT.. | |
| 04/02 | UNIQURE N.V.: Entry into a Material Definitive Agreement (form 8-K) | |
| 04/02 | EAHAD 2022 - FINAL ANALYSIS FROM THE: Stable Steady-State Efficacy and Safety of Etranaco.. | |
| 04/02 | Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic E.. | |
| 20/01 | Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, .. | |
| 2021 | UniQure Unit Enters Into $6.5 Million Lease Agreement in Massachusetts | |
| 2021 | UNIQURE N.V.: Entry into a Material Definitive Agreement (form 8-K) | |
| 2021 | UNIQURE N: Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AM.. | |
| 2021 | UNIQURE N.V.: Entry into a Material Definitive Agreement, Creation of a Direct Financial .. | |
| 2021 | uniQure N.V. Enters into Third Amended and Restated Loan and Security Agreement | |
| 2021 | Health Care Up On Defensive Bias -- Health Care Roundup | |
| 2021 | Global biotherapeutics - CSL Behring Receives Accelerated CHMP Assessment for Etranacog.. | |
| 2021 | UniQure Says Initial Data From Phase 1/2 Trial Support Tolerability of AMT-130 in Patie.. | |
| 2021 | TRANSCRIPT: uniQure N.V. - Special Call | |
| 2021 | uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT.. | |
| 2021 | uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT.. | |
| 2021 | CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for Euro.. | |
| 2021 | UNIQURE N: and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of .. | |
| 2021 | UNIQURE N.V.: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 2021 | CSL Behring and uniQure N.V. Announce Etranacogene Dezaparvovec, an Investigational Ade.. | |
| 2021 | Health Care Stocks Lower Ahead of Thursday Open | |
| 2021 | UniQure, CSL Behring Say Late-Stage Trial of Hemophilia Treatment Meets Primary Endpoin.. | |
| 2021 | uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of E.. | |
| 2021 | uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of E.. | |
| 2021 | INSIDER SELL: Uniqure | |
| 2021 | UniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in P.. | |
| 2021 | UniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board in Pha.. | |
| 2021 | UniQure to Participate in Upcoming Industry Conferences in November | |
| 2021 | UNIQURE N: Announces Third Quarter 2021 Financial Results and Highlights Recent Company P.. | |
| 2021 | UNIQURE N: Management's Discussion and Analysis of Financial Condition and Results of Ope.. | |
| 2021 | UNIQURE N: Narrows Loss in Q3, Revenue Climbs | |
| 2021 | UniQure N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe.. | |
| 2021 | UNIQURE: Q3 Earnings Snapshot | |
| 2021 | UNIQURE N: Earnings Flash (QURE) UNIQURE Reports Q3 Revenue $2M | |
| 2021 | UNIQURE N: Announces Third Quarter 2021 Financial Results and Highlights Recent Company P.. | |
| 2021 | UNIQURE N.V.: Submission of Matters to a Vote of Security Holders (form 8-K) | |
| 2021 | UNIQURE N: ESGCT 2021 - Pre-Clinical Proof of Concept of an AAV5-GLA Gene Therapy for Fab.. | |
| 2021 | UNIQURE N: Announces the Appointment of Rachelle Jacques to its Board of Directors | |
| 2021 | UniQure N.V. Appoints Rachelle Jacques?to its Board of Directors | |
| 2021 | TRANSCRIPT: uniQure N.V. - Shareholder/Analyst Call | |
| 2021 | UNIQURE N: Announces Presentations at the Annual Meeting of The European Society of Gene .. | |
| 2021 | INSIDER SELL: Uniqure | |
| 2021 | UNIQURE N: to Participate in Multiple Upcoming Industry Conferences in October | |
| 2021 | INSIDER SELL: uniQure | |
| 2021 | UNIQURE N.V.(NASDAQGS: QURE) added to S&P 600 | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Nederlands (Nederland)
Nederlands (België)
Rapporto
